2022 World Conference on Lung Cancer (ePosters)-EP14.05-002. Impact of Body Mass Index on Survival in Patients with Small Cell Lung Cancer

EP14.05-002. Impact of Body Mass Index on Survival in Patients with Small Cell Lung Cancer

Pdf Summary

A recent study investigated the impact of Body Mass Index (BMI) on the survival of patients with Small Cell Lung Cancer (SCLC). SCLC is a type of lung cancer with a poor prognosis, despite advances in treatment. Previous studies in patients with non-SCLC treated with immunotherapy have suggested that BMI may be a potential biomarker of treatment benefit.<br /><br />The study included 264 patients with SCLC, of which 169 were diagnosed at stage IV and 95 were diagnosed at stages I-III. The patients' characteristics were evaluated, including age, gender, smoking history, performance status, treatment received, and BMI. BMI was categorized as underweight, normal weight, overweight, or obese.<br /><br />The results showed that in patients with stage IV SCLC treated with standard chemotherapy, BMI did not have an impact on outcomes. However, in patients with stages I-III SCLC, BMI was found to be associated with overall survival. Underweight patients had a decreased median overall survival, while obese patients had an increased median overall survival. These findings suggest that BMI may have prognostic value for patients with stages I-III SCLC.<br /><br />Further studies are needed to confirm the role of BMI as a prognostic biomarker in SCLC. The study highlights the importance of considering BMI as a potential factor in the evaluation of SCLC patients and may have implications for treatment strategies and patient management.

Asset Subtitle

Alejandro Rios-Hoyo

Meta Tag

Speaker Alejandro Rios-Hoyo

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - RW/SOC

Keywords

Body Mass Index

BMI

survival

patients

Small Cell Lung Cancer

SCLC

prognosis

treatment benefit

stage IV

stages I-III